Company / Return on Assets (ROA)
Taysha Gene Therapies, Inc. Return on Assets (ROA) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-31.8%
FY2025
5-year range
-138.2% / -31.8%
FY2021-FY2025
Trend
+54.4%
vs FY2024
Sector context
#138 of 213
Health Care
What the data says
At -31.8%, Taysha Gene Therapies, Inc.'s return on assets (roa) ranks #138 of 213 in the Health Care sector. Return on Assets (ROA) has increased for 3 consecutive years, from -138.2% in FY2022 to -31.8% in FY2025.
Based on SEC 10-K filings.
-31.8% in FY2025 with a 5-year CAGR of -8.6%.
Improved from -96.1% to -31.8% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +106.5pp
- 5-Year Change
- -8.6pp
- 10-Year Change
- -
Sector benchmark
#138 of 213 in Health CareTop 65% of 213This company -31.8% Sector average -24.1%
▼
-31.5% below sector average
Key checks
Key Insights
- Taysha Gene Therapies, Inc.'s return on assets (roa) has grown for 3 consecutive years.
- In FY2025, return on assets (roa) increased 54.4% year-over-year.
- Currently 7.6pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -31.8% | +54.4% |
| FY2024 | -69.6% | +27.6% |
| FY2023 | -96.1% | +30.5% |
| FY2022 | -138.2% | -69.4% |
| FY2021 | -81.6% | -251.9% |
| FY2020 | -23.2% | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026